Physician profile
Maureen Offiah
NPI 1760896195
$274,514.75
in general payments reported to CMS, 2019-2025
39 companies · $254K in 2025
The $254K reported for 2025 was more than what 99% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $993 · 2020: $902 · 2021: $1,883 · 2022: $1,490 · 2023: $4,776 · 2024: $10K · 2025: $254K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $126K · Consulting Fee: $98K · Travel and Lodging: $30K · Food and Beverage: $15K · Education: $300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $126,162.50 |
| Consulting Fee | $98,133.20 |
| Travel and Lodging | $30,061.34 |
| Food and Beverage | $14,589.50 |
| Education | $299.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $86,726.51 | 2020-2025 | Anzupgo, Adbry, Spevigo |
| Arcutis Biotherapeutics, INC. | $79,039.52 | 2023-2025 | Zoryve |
| Amgen INC. | $40,449.00 | 2019-2025 | Otezla, Otezla |
| Kowa Pharmaceuticals America, INC. | $26,136.62 | 2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $13,270.02 | 2023-2025 | Sotyktu |
| Ucb, INC. | $9,967.69 | 2019-2025 | Bimzelx, Cimzia |
| Genzyme Corporation | $7,482.44 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $2,367.20 | 2019-2025 | |
| Abbvie INC. | $1,592.97 | 2019-2025 | |
| Organon LLC | $1,590.87 | 2025 | Vtama |
| Janssen Biotech, INC. | $874.73 | 2019-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $689.95 | 2020-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $589.34 | 2020-2025 | |
| Incyte Corporation | $579.25 | 2021-2025 | Opzelura |
| Pfizer INC. | $528.78 | 2019-2025 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $466.99 | 2020-2025 | Arazlo, Cabtreo, Duobrii |
| Galderma Laboratories, L.P. | $454.13 | 2020-2025 | Nemluvio, Aklief, Dysport |
| Dermavant Sciences, INC. | $288.69 | 2022-2024 | Vtama |
| Lilly USA, LLC | $254.43 | 2019-2025 | Ebglyss, Taltz, Olumiant |
| Janssen Scientific Affairs, LLC | $242.78 | 2021-2025 | Tremfya |
| Biofrontera INC. | $116.62 | 2020-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Revance Therapeutics, INC. | $100.00 | 2025 | Daxxify |
| Epi Health, LLC | $85.20 | 2019-2022 | |
| Gilead Sciences, INC. | $77.46 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $76.63 | 2023-2025 | Spevigo |
| Dusa Pharmaceuticals, INC. | $74.86 | 2019 | |
| Verrica Pharmaceuticals INC. | $48.36 | 2023-2024 | Ycanth |
| Mayne Pharma Commercial LLC | $48.02 | 2020-2023 | |
| Medimetriks Pharmaceuticals, INC. | $46.95 | 2025 | Neo-Synalar |
| Allergan, INC. | $44.43 | 2021 | |
| Genentech USA, INC. | $39.38 | 2019 | |
| Botanix Sb INC | $30.80 | 2025 | Sofdra |
| Almirall LLC | $30.12 | 2021 | |
| Vyne Pharmaceuticals INC. | $23.61 | 2021 | |
| Convatec INC. | $21.47 | 2024 | |
| Strata Skin Sciences, INC. | $16.79 | 2024 | Xtrac |
| Ani Pharmaceuticals, INC. | $15.93 | 2023 | Apexicon E |
| Global Blood Therapeutics, INC. | $14.95 | 2020 | |
| Celgene Corporation | $11.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maureen Offiah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.